India's Glenmark May Shelve Research On Metabolic Disorders Due To Tougher Regulatory Standards
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - After a prolonged decision-making process, India's Glenmark Pharmaceuticals is likely to halt development of potential compounds melogliptin (GRC 8200) and pain management drug GRC 6211